Marinomed Biotech has announced that a Phase 3 trial of Budesolv budesonide nasal spray has met its primary endpoint. Without providing any specific data, the company said that, “The top line results are now available and show that Budesolv achieves at least the same effect as the product which is currently on the market, with a significantly lower dose.” According to Marinomed, detailed results from the study will be published by mid-year.
Budesolv, which the company is developing for the treatment of allergic rhinitis, is formulated using Marinomed’s Marinosolv solubility enhancement platform. According to the Marinomed web site, Marinosolv includes saponins derived from licorice and horse chestnut plants and “enables novel stable formulations in a micellar solution of practically insoluble compounds such as corticosteroids or immunosuppressants.”
The company has also developed nasal sprays based on a carrageenan-based polymer.
Read the Marinomed Biotech press release.
